According to the Centers for Disease Control and Prevention, the FDA-approved H1N1 vaccine will be manufactured in several formulations, including multi-dose vials (to be administered on two occasions, four weeks apart) that will contain thimerosal and single-dose units, which will not require the preservative.
In addition, the live-attenuated version of the vaccine (one that contains bacteria or viruses that have been altered so they can’t cause disease), administered intranasally, will be produced in single units that do not contain thimerosal.
Doctor defends vaccine
Dr. Thomas Bent of the Laguna Beach Community Clinic, who is also president of the California Academy of Family Physicians, and Perry Sheidayi of the Sleep Hollow Clinic, not only condone administering the vaccine to all high risk groups, but are pushing for it.